-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下：LDOS第一季度业绩稳健，调整后每股收益为3.13美元，高于去年同期的2.97美元，超出市场预期0.22美元。营收同比增长4%（有机增长3%），达到44亿美元，超出预期1.1亿美元，主要得益于情报、商业能源基础设施和空中交通管理方面的需求增长。本季度最突出的表现是现金流的卓越表现，经营现金流达到3.01亿美元，高于去年同期的5800万美元；自由现金流也从3600万美元增至2.7亿美元，转化率达到67%，这主要得益于稳健的EBITDA和有效的营运资本管理。然而，由于收购相关成本，调整后EBITDA利润率下降20个基点至14.0%。净订单额达33亿美元，季度订单出货比为0.8倍，但过去12个月的比率仍保持在1.1倍的健康水平。总积压订单额达到484亿美元，其中已融资积压订单额为96亿美元，分别同比增长4%和31%，这为未来的收入提供了更清晰的预期。
Related Articles
Australia
Citigroup Adjusts Price Target on Marathon Petroleum to $257 From $243, Maintains Neutral Rating
Marathon Petroleum (MPC) has an average rating of overweight and mean price target of $253.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $256.58, Change: $+4.04, Percent Change: +1.60%
$MPC
Research
Research Alert: Peg Reports Strong Q1 Beat; On Track For $4.2b Capex And 7% Eps Growth In 2026
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PEG reported Q1 2026 adjusted EPS of $1.55 vs. $1.43 (+8.4% Y/Y, +8.5% vs. consensus), supported by higher PSE&G margins from regulated infrastructure investments and customer growth, partially offset by higher depreciation and interest expense. PSEG Power earnings increased due to higher realized power prices and lower O&M costs, offset by lower generation volumes. We see the company as on target for $4.2B full-year 2026 capex guidance after deploying ~$0.8B in Q1, while PEG maintained long-term targets including $24B-$28B total capex for 2026-2030 and a 6%-7.5% rate base CAGR. Management reaffirmed its 2026 EPS guidance of $4.28-$4.40, representing ~7% growth at the midpoint. Both residential electric and gas customers increased ~1% on a trailing-12-month basis, which we think reflects continued execution of the regulated investment program. Annualized dividends were increased ~6% to $2.68 for 2026. We view this as a competitive growth rate amongst Multi-Utility peers.
$PEG
Australia
Merck Completes Terns Pharmaceuticals Acquisition
Merck (MRK) said Tuesday it has completed the acquisition of Terns Pharmaceuticals after a cash tender offer at $53 per share.Terns' stock will no longer be listed on Nasdaq, it said.The deal will result in a charge to research and development expense of about $2.35 per share, included in Q2 and full year 2026 GAAP and non-GAAP results, Merck said.GAAP and non-GAAP EPS are also expected to take a hit of about $0.12 a share in 2026 on costs associated with advancing TERN-701 and costs of financing, it added.Price: $113.21, Change: $+0.10, Percent Change: +0.09%
$MRK$TERN